Utilization of antidepressants, anxiolytics, and hypnotics during the COVID-19 pandemic

[1]  Ravi B. Parikh,et al.  The COVID-19 Pandemic and In-Person Visit Rate Disruptions Among Patients With Hematologic Neoplasms in the US in 2020 to 2021 , 2023, JAMA network open.

[2]  L. Grzeskowiak,et al.  Dispensing of psychotropic medications to Australian children and adolescents before and during the COVID‐19 pandemic, 2013–2021: a retrospective cohort study , 2023, The Medical journal of Australia.

[3]  L. Lopes,et al.  Sales trends of psychotropic drugs in the COVID-19 pandemic: A national database study in Brazil , 2023, Frontiers in Pharmacology.

[4]  P. F. Martínez,et al.  Psychotropic consumption before and during COVID-19 in Asturias, Spain , 2023, BMC Public Health.

[5]  M. Uimonen,et al.  Primary care visits due to mental health problems and use of psychotropic medication during the COVID-19 pandemic in Finnish adolescents and young adults , 2023, Child and Adolescent Psychiatry and Mental Health.

[6]  Maria A Rogers,et al.  ADHD Symptoms Increased During the Covid-19 Pandemic: A Meta-Analysis , 2023, Journal of attention disorders.

[7]  Yonatan Bilu,et al.  Data-Driven Assessment of Adolescents’ Mental Health During the COVID-19 Pandemic , 2023, Journal of the American Academy of Child & Adolescent Psychiatry.

[8]  T. Aspelund,et al.  Trends in incident diagnoses and drug prescriptions for anxiety and depression during the COVID-19 pandemic: an 18-month follow-up study based on the UK Biobank , 2023, Translational Psychiatry.

[9]  Dayani Galato,et al.  Dispensing of psychotropic drugs in the Brazilian capital city before and during the COVID-19 pandemic (2018–2020) , 2022, Frontiers in Pharmacology.

[10]  Z. Silver,et al.  Prevalence of mental health symptoms in children and adolescents during the COVID‐19 pandemic: A meta‐analysis , 2022, Annals of the New York Academy of Sciences.

[11]  Julien S. Baker,et al.  Effect of the COVID-19 pandemic on the psychotropic drug consumption , 2022, Frontiers in Psychiatry.

[12]  P. B. Jensen,et al.  Psychotropic Medication Use and Psychiatric Disorders During the COVID-19 Pandemic Among Danish Children, Adolescents, and Young Adults. , 2022, JAMA psychiatry.

[13]  N. Magrini,et al.  Impact of COVID-19 pandemic on medication use in the older Italian population , 2022, Aging Clinical and Experimental Research.

[14]  Sara García Diez,et al.  Impacto del confinamiento por COVID-19 en la prescripción de benzodiacepinas , 2022, Atención Primaria.

[15]  C. Cattuto,et al.  Psychotropic drug purchases during the COVID-19 pandemic in Italy and their relationship with mobility restrictions , 2022, Scientific Reports.

[16]  M. Tiger,et al.  Utilization of antidepressants, anxiolytics, and hypnotics during the COVID-19 pandemic in Scandinavia , 2022, Journal of Affective Disorders.

[17]  D. Rujescu,et al.  Prescriptions of psychopharmacologic drugs in Austria in 2019 and 2020 – Implications of the COVID-19 pandemic , 2022, European Psychiatry.

[18]  B. Mustanski,et al.  Prevalence and correlates of stocking up on drugs during the COVID-19 pandemic: Data from the C3PNO Consortium , 2022, Drug and Alcohol Dependence.

[19]  D. Nolfi,et al.  Sleep in Children With Neurodevelopmental Disabilities During COVID-19: An Integrative Review , 2022, Journal of Pediatric Health Care.

[20]  Davi Azevedo Ferreira,et al.  Prescription and Dispensing of Benzodiazepines in Times of the Covid-19 Pandemic in Brazil / Prescrição e dispensação de benzodiazepínicos em tempos de pandemia da covid-19 no brasil , 2022, Revista de Pesquisa Cuidado é Fundamental Online.

[21]  E. Caputo,et al.  Prevalence of anxiety during the COVID-19 pandemic: A systematic review and meta-analysis of over 2 million people , 2022, Journal of Affective Disorders.

[22]  S. dosReis,et al.  Psychotropic Prescriptions During the COVID-19 Pandemic Among U.S. Children and Adolescents Receiving Mental Health Services. , 2022, Journal of child and adolescent psychopharmacology.

[23]  D. O’Reilly,et al.  Impact of the COVID-19 pandemic on psychotropic medication uptake: time-series analysis of a population-wide cohort , 2022, The British Journal of Psychiatry.

[24]  A. Sourander,et al.  A systematic review of the mental health changes of children and young people before and during the COVID-19 pandemic , 2022, European Child & Adolescent Psychiatry.

[25]  Ahmad F. Alenezi,et al.  The prevalence and severity of insomnia symptoms during COVID-19: A global systematic review and individual participant data meta-analysis , 2022, Sleep medicine.

[26]  B. Wettermark,et al.  Comparison of drug prescribing before and during the COVID‐19 pandemic: A cross‐national European study , 2022, Pharmacoepidemiology and drug safety.

[27]  Y. Goldberg,et al.  Increased incident rates of antidepressant use during the COVID-19 pandemic: interrupted time-series analysis of a nationally representative sample , 2022, Psychological Medicine.

[28]  J. Reutfors,et al.  Increased antidepressant use during the COVID-19 pandemic: Findings from the Friuli Venezia Giulia region, Italy, 2015–2020 , 2022, Psychiatry Research.

[29]  C. Cesta,et al.  Antimicrobial use in Sweden during the COVID-19 pandemic: prescription fill and inpatient care requisition patterns , 2022, BMC Infectious Diseases.

[30]  C. Bousman,et al.  Dispensing patterns of mental health medications before and during the COVID-19 pandemic in Alberta, Canada: An interrupted time series analysis , 2022, International journal of psychiatry in medicine.

[31]  J. A. Delaney,et al.  Psychotropic Medication Use Before and During COVID-19: A Population-Wide Study , 2022, Frontiers in Pharmacology.

[32]  P. Nabbe,et al.  Analysis of Drug and Health Resource Use Before and After COVID-19 Lockdown in a Population Undergoing Treatment for Depression or Anxiety , 2022, Frontiers in Psychology.

[33]  Bruno José Nievas-Soriano,et al.  Consumption of Psychiatric Drugs in Primary Care during the COVID-19 Pandemic , 2022, International journal of environmental research and public health.

[34]  D. Boulware,et al.  Fluvoxamine for Outpatient Management of COVID-19 to Prevent Hospitalization , 2022, JAMA network open.

[35]  L. Gómez-Oliván,et al.  Consumption and ocurrence of antidepressants (SSRIs) in pre- and post-COVID-19 pandemic, their environmental impact and innovative removal methods: A review. , 2022, The Science of the total environment.

[36]  S. Pearson,et al.  Changes in antidepressant use in Australia: A nationwide analysis (2015–2021) , 2022, The Australian and New Zealand journal of psychiatry.

[37]  Yan Xie,et al.  Risks of mental health outcomes in people with covid-19: cohort study , 2022, BMJ.

[38]  Noah H. Crampton,et al.  Effects of COVID-19 pandemic on anxiety and depression in primary care: A retrospective cohort study , 2022, Journal of Affective Disorders.

[39]  M. Czech,et al.  Impact of COVID-19 Pandemic on the Use of Antidepressant and Antianxiety Pharmaceuticals as Well as Sick Leave in Poland , 2022, International journal of environmental research and public health.

[40]  P. Cortesi,et al.  Antidepressants Drug Use during COVID-19 Waves in the Tuscan General Population: An Interrupted Time-Series Analysis , 2022, Journal of personalized medicine.

[41]  W. Gellad,et al.  The global impact of COVID-19 on drug purchases: A cross-sectional time series analysis , 2021, Journal of the American Pharmacists Association.

[42]  A. Håkansson,et al.  Impact of the COVID-19 Pandemic on the General Mental Health in Sweden: No Observed Changes in the Dispensed Amount of Common Psychotropic Medications in the Region of Scania , 2021, Frontiers in Psychiatry.

[43]  T. Gomes,et al.  The effects of COVID‐19 on the dispensing rates of antidepressants and benzodiazepines in Canada , 2021, Depression and anxiety.

[44]  S. Selvaraj,et al.  Prescription fill patterns for benzodiazepine and opioid drugs during the COVID-19 pandemic in the United States , 2021, Drug and Alcohol Dependence.

[45]  M. Olfson,et al.  Psychotropic medication prescribing during the COVID-19 pandemic , 2021, Medicine.

[46]  M. Raji,et al.  Trends in the Use of Benzodiazepines, Z-Hypnotics, and Serotonergic Drugs Among US Women and Men Before and During the COVID-19 Pandemic , 2021, JAMA network open.

[47]  C. Imperatori,et al.  Psychotropic medications sales during COVID-19 outbreak in Italy changed according to the pandemic phases and related lockdowns , 2021, Public Health.

[48]  M. T. Herdeiro,et al.  Prescription of anxiolytics, sedatives, hypnotics and antidepressants in outpatient, universal care during the COVID-19 pandemic in Portugal: a nationwide, interrupted time-series approach , 2021, Journal of Epidemiology & Community Health.

[49]  D. Christakis,et al.  The Association Between School Closures and Child Mental Health During COVID-19 , 2021, JAMA network open.

[50]  C. Cesta,et al.  Patterns of prescription dispensation and over-the-counter medication sales in Sweden during the COVID-19 pandemic , 2021, PloS one.

[51]  R. Conti,et al.  Prescription Drug Dispensing to US Children During the COVID-19 Pandemic , 2021, Pediatrics.

[52]  M. Mazidi,et al.  Prevalence of mental health problems among children and adolescents during the COVID-19 pandemic: A systematic review and meta-analysis , 2021, Journal of Affective Disorders.

[53]  M. Stein,et al.  Decline In New Starts Of Psychotropic Medications During The COVID-19 Pandemic. , 2021, Health affairs.

[54]  M. Sánchez Díaz,et al.  Trends in the Use of Anxiolytics in Castile and Leon, Spain, between 2015–2020: Evaluating the Impact of COVID-19 , 2021, International journal of environmental research and public health.

[55]  Helen Onyeaka,et al.  COVID-19 pandemic: A review of the global lockdown and its far-reaching effects , 2021, Science progress.

[56]  Richard Armitage.  Antidepressants, primary care, and adult mental health services in England during COVID-19 , 2021, The Lancet Psychiatry.

[57]  S. Tasnim,et al.  Prevalence of anxiety and depression in South Asia during COVID-19: A systematic review and meta-analysis , 2020, Heliyon.

[58]  J. Ludvigsson.  The first eight months of Sweden’s COVID‐19 strategy and the key actions and actors that were involved , 2020, Acta paediatrica.

[59]  K. Kim,et al.  What Is COVID-19? , 2020, Frontiers for Young Minds.

[60]  Andrew K. Przybylski,et al.  Multidisciplinary research priorities for the COVID-19 pandemic: a call for action for mental health science , 2020, The Lancet Psychiatry.

[61]  R. Mojtabai,et al.  Antidepressant use in 27 European countries: Associations with sociodemographic, cultural and economic factors , 2015, British Journal of Psychiatry.

[62]  L. Bartolomeo,et al.  this paper , 2009, Engineering and Technology Journal.